Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) EBT (2019 - 2025)

Goldenwell Biotech filings provide 7 years of EBT readings, the most recent being -$7985.0 for Q3 2025.

  • On a quarterly basis, EBT rose 65.38% to -$7985.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $20383.0, a 116.33% increase, with the full-year FY2024 number at -$131498.0, down 12.05% from a year prior.
  • EBT hit -$7985.0 in Q3 2025 for Goldenwell Biotech, down from -$5220.0 in the prior quarter.
  • In the past five years, EBT ranged from a high of $67965.0 in Q4 2024 to a low of -$920332.0 in Q4 2022.
  • Median EBT over the past 5 years was -$27084.0 (2023), compared with a mean of -$68627.5.
  • Biggest five-year swings in EBT: plummeted 16234.25% in 2021 and later skyrocketed 426.77% in 2024.
  • Goldenwell Biotech's EBT stood at -$29554.0 in 2021, then plummeted by 3014.07% to -$920332.0 in 2022, then skyrocketed by 97.74% to -$20799.0 in 2023, then skyrocketed by 426.77% to $67965.0 in 2024, then crashed by 111.75% to -$7985.0 in 2025.
  • The last three reported values for EBT were -$7985.0 (Q3 2025), -$5220.0 (Q2 2025), and -$34377.0 (Q1 2025) per Business Quant data.